Kaye Mark 4

What Happened
Mark Kaye, a director of CONMED Corporation (CNMD), reported the exercise/conversion of a derivative on February 24, 2026. The Form 4 shows 152 units were acquired and simultaneously reported as disposed (both at $0.00). The filing identifies these instruments as restricted stock units (RSUs) that were converted into common shares; no cash proceeds or sale price are reported.

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (within the usual 2-business-day reporting window).
• Reported amounts: 152 shares acquired and 152 shares disposed, price per share reported as $0.00; total cash value shown as $0.
• Transaction code: M = exercise or conversion of a derivative security.
• Shares owned after the transaction: not specified in the filing.
• Footnote: Each RSU represents a contingent right to one share under the company’s 2020 Non-Employee Director Equity Compensation Plan; RSUs generally vest 100% after one year and vest immediately upon termination of director service.

Context
This is a conversion/settlement of RSUs (a compensation/award event) rather than an open-market purchase or sale. The $0.00 reporting indicates the filing documents the conversion/settlement of derivative units into shares rather than a cash sale of stock. Such award settlements are routine for equity-compensated directors and do not by themselves indicate a buy or sell decision.